Global Human Papillomavirus Infection Drug Market and Clinical Trials Insight 2023

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-human-papillomavirus-infection-drug-market-and-clinical-trials-insight-2023.php

 

Table of Contents

 

1. Introduction to Human Papillomavirus Infection

  1.1 Overview

  1.2 Pathogenicity and Diversity of Human Papillomavirus

    1.2.1 Alpha Papillomaviruses

    1.2.2 Beta Papillomaviruses

    1.2.3 Gamma Papillomaviruses

2. Pathophysiology of Human Papillomavirus

  2.1 Life Cycle of Human Papillomavirus

    2.1.1 Primary Infection of Epidermis Layer

    2.1.2 Genome Maintenance

    2.1.3 Proliferative Phase

    2.1.4 Viral Genome Amplification

    2.1.5 Virus Assembly and Release

  2.2 Molecular Mechanism of Human Papillomavirus to Induce Disease

3. Response of Immune System Against Human Papillomavirus

  3.1 Innate Immunity

  3.2 Adaptive Immunity

4. Clinical Management Strategies Against Human Papillomavirus Infection

  4.1 Vaccination Approach for Human Papillomavirus

  4.2 Therapeutic Drugs Targets

    4.2.1 Interferon

    4.2.2 RNA Interference based Therapies

    4.2.3 Natural or Herbal Derivatives

5. Emerging Therapies for Treatment of Infection

  5.1 Live Vector based Vaccines

  5.2 Protein or Peptide based Vaccines

  5.3 Nucleic Acid based Vaccines

  5.4 Whole Cell based Vaccines

6. Approved Drugs for Treating Human Papillomavirus Infection: Clinical, Drug Class and Patent Insight

  6.1 Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil and Silgard)

  6.2 Interferon alpha-2b (Intron A, Viraferon and Virtron)

  6.3 Tretinoin (Acnisdin Retinoico, Avita, Dermojuventus, Loderm Retinoico, Retirides, Vesanoid, Vitamin-A Acid and Vitanol)

  6.4 Imiquimod (Aldara, Beselna Cream 5%, Vyloma and Zyclara)

  6.5 Human Papillomavirus Vaccine Recombinant Bivalent  (Cervarix)

  6.6 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)

  6.7 Interferon-alpha-n3 (Alferon LDO, Alferon N, Alferon N Gel, Alferon N Injection, Alferon N LDO, Altemol and Naturaferon)

  6.8 Polyphenon E (Polyphenon E and Veregen)

  6.9 Interferon Gamma Biosimilar (Ingaron)

7. Global Human Papillomavirus Infection Market Analysis

  7.1 Introduction to Infectious Disease Market

  7.2 Global Human Papillomavirus Market Analysis

8. Global Human Papillomavirus Infection Drug Market Dynamics

  8.1 Favorable Parameters

  8.2 Challenges to Market Growth

9. Global Human Papillomavirus Infection Drug Market Future Perspective

10. Global Human papillomavirus Infections Drug Clinical Pipeline by Company and Phase

  10.1 Research

  10.2 Preclinical

  10.3 Phase-I

  10.4 Phase-I/II

  10.5 Phase-II

  10.6 Phase-II/III

  10.7 Phase-III

11. Competitive Landscape

  11.1 3M Pharmaceuticals

  11.2 Aclaris Therapeutics

  11.3 Mylan Pharmaceuticals

  11.4 Biogen Idec

  11.5 Cutanea Life Sciences

  11.6 Hemispherx

  11.7 Inovio Pharmaceuticals

  11.8 ISA Pharmaceuticals

  11.9 Lees Pharmaceutical Holdings

  11.10 MedImmune

  11.11 Merck

  11.12 Nielsen BioSciences

  11.13 Novan

 

Figure 1-1: Structural Components of Viral Particles

Figure 1-2: Fundamental Constituents of Human Papillomavirus

Figure 1-3: Classification and Diversity of Human Papillomavirus

Figure 2-1: Life Cycle of Human Papillomavirus to Cause the Infection

Figure 2-2: Multistep Model of Cancer Development by Human Papillomavirus

Figure 3-1: HPV Infection Model and Activation of Innate Immune Response

Figure 3-2: Adaptive Immune Response to Human Papillomavirus Infection

Figure 4-1: Clinical Management Strategies for Treating Human Papillomavirus Infections

Figure 4-2: HPV L1 VLP Vaccine Mechanism of Action

Figure 4-3: Response of Interferons with Human Papillomavirus

Figure 7-1: Global andndash; Infectious Disease Diagnostic Market Growth Estimation (US$ Million), 2016-2023

Figure 7-2: Global Infectious Therapeutics Market Growth (US$ Billion), 2016-2023

Figure 7-3: Global Viral Infections Market Growth Estimation (US$ Billion), 2016-2023

Figure 7-4: Global – HPV Therapeutics Market (US$ Billion), 2016-2023

Figure 7-5: Global – Human Papillomavirus Infection Drug Pipeline by Phase (%), 2017 till 2023

Figure 7-6: Global – Human Papillomavirus Infection Drug Pipeline by Phase (Number), 2017 till 2023

Figure 7-7: Global andndash; Active and Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (%), 2017 till 2023

Figure 7-8: Global andndash; Active and Inactive Human Papillomavirus Infection Drug in Pipeline by Phase (Number), 2017 till 2023

Figure 8-1: Global – Favorable Parameters to Human Papilloma Virus Market Growth

Figure 8-2: Global – Challenges to Human Papilloma Virus Infection Development

List of Tables

Table 3-1:  List of RNA Studies Targeting HPV E6 and E7

Table 3-2: Molecular Targeting HPV and Host Cellular Factors Interaction Using Natural and Herbal Derivatives